Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for March 5, 2025, at 9:50 am ET in Boston.
Interested parties can access a live webcast of the presentation through the Events and Presentations section on Protara's investor relations website at https://ir.protaratx.com. The presentation recording will be available for a time after the event.
Protara Therapeutics (Nasdaq: TARA), un'azienda in fase clinica focalizzata sullo sviluppo di terapie per il cancro e malattie rare, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La direzione dell'azienda parteciperà a una chiacchierata informale programmata per il 5 marzo 2025, alle 9:50 ET a Boston.
Le parti interessate possono accedere a una diretta streaming della presentazione attraverso la sezione Eventi e Presentazioni sul sito web delle relazioni con gli investitori di Protara all'indirizzo https://ir.protaratx.com. La registrazione della presentazione sarà disponibile per un certo periodo dopo l'evento.
Protara Therapeutics (Nasdaq: TARA), una empresa en etapa clínica centrada en el desarrollo de terapias para el cáncer y enfermedades raras, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. La dirección de la empresa participará en una charla informal programada para el 5 de marzo de 2025, a las 9:50 am ET en Boston.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Eventos y Presentaciones en el sitio web de relaciones con inversores de Protara en https://ir.protaratx.com. La grabación de la presentación estará disponible por un tiempo después del evento.
Protara Therapeutics (Nasdaq: TARA)는 암 및 희귀 질환 치료제 개발에 집중하는 임상 단계 회사로, TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사 경영진은 2025년 3월 5일 오전 9시 50분 ET에 보스턴에서 예정된 파이어사이드 채팅에 참여할 것입니다.
관심 있는 분들은 Protara의 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다. 발표 녹화는 행사 후 일정 기간 동안 이용 가능합니다.
Protara Therapeutics (Nasdaq: TARA), une entreprise en phase clinique axée sur le développement de thérapies pour le cancer et les maladies rares, a annoncé sa prochaine participation à la 45e Conférence Annuelle de Santé de TD Cowen. La direction de l'entreprise participera à une discussion informelle prévue pour le 5 mars 2025 à 9h50 ET à Boston.
Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Événements et Présentations sur le site web des relations avec les investisseurs de Protara à l'adresse https://ir.protaratx.com. L'enregistrement de la présentation sera disponible pendant un certain temps après l'événement.
Protara Therapeutics (Nasdaq: TARA), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Krebs und seltene Krankheiten konzentriert, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Das Management des Unternehmens wird an einem geplanten Fireside-Chat am 5. März 2025 um 9:50 Uhr ET in Boston teilnehmen.
Interessierte Parteien können über den Bereich Veranstaltungen und Präsentationen auf der Investor-Relations-Website von Protara unter https://ir.protaratx.com auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird für eine gewisse Zeit nach der Veranstaltung verfügbar sein.
- None.
- None.
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 9:50 am ET in Boston.
A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When is Protara Therapeutics (TARA) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Protara Therapeutics' (TARA) presentation at the TD Cowen conference?
What type of presentation will TARA deliver at the TD Cowen Healthcare Conference?
Will TARA's TD Cowen conference presentation be available for replay?
